Replies to post #787356 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

Watch for when all the .24 cent warrants are finally converted.
Isn't it strange how they are desperately trying to keep it at .25 for now?
Coincidence? Who knows... 😜

[SkyLimit2022]

ASw,



Your statement is almost accurate—your opinions have nothing at all to do with the MHRA’s standards 😶

Fact ✅️:
Regulatory agencies may choose to consider independently peer-reviewed publications as part of their overall analysis.

Fact ✅:
The MHRA has already awarded several approvals, including their approval of the MIA (a prerequisite of the MAA) & their ongoing support of the DCVax-L Specials Program.

Mar 2023, NWBO & Advent MIA Approval


Aug 2022, NWBO PIP Approval


Dec 2021, NWBO & Advent GMP License Approval



Regarding the P3, enrollment completed years before 2020, but patients continued to be treated & followed under the trial protocol as trial participants after enrollment closed. The P3 trial concluded in 2020, & data lock happened in Q4 of 2020…

COMBOS with checkpoint inhibitors & other agents are much more recent & have reached P2 for both DCVax-L & the Roswell DC technology platform.

⭐️Combo is King!⭐️




⭐️ AACR Advances in Ovarian Cancer Research

⭐️ NWBO to Acquire Advent BioServices

⭐️ Recent Conference

⭐️ DCVax-L Combo PII UCLA

⭐️ DC Combo PII Roswell Park

⭐️ 10-Q Quarterly Report

⭐️ 10-K Annual Report

⭐️ NICE UK 🇬🇧 DCVax-L

⭐️ ASM June 29, 2024

⭐️ Manufacturing Technology

⭐️ NWBO Acquires Flaskworks

⭐️ Roswell Park IP Portfolio

⭐️ TLR3 agonist Ampligen (rintatolimod)

⭐️ Next Generation Dendritic Cell Treatments



AI Fact-Checking

[Steady_T]

Nor does your opinion have anything to do with MHRA standards.

Given the choice between the you and the JAMA authors, the choice is clear.